Ignite Creation Date:
2025-12-24 @ 4:49 PM
Ignite Modification Date:
2025-12-25 @ 2:34 PM
Study NCT ID:
NCT03839550
Status:
UNKNOWN
Last Update Posted:
2019-02-15
First Post:
2019-02-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-02-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2020-02-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-02-28
Completion Date Type:
ESTIMATED
First Submit Date:
2019-02-11
First Submit QC Date:
None
Study First Post Date:
2019-02-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-02-11
Last Update Post Date:
2019-02-15
Last Update Post Date Type:
ACTUAL